MedTrace Logo

Biomarkers for the Progression of IgA Nephropathy

NCT02529722 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2015-08-20

No results posted yet for this study

Summary

IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease. IgAN has an incidence of 8-25 new cases/year/per million age-related population in adults and 3-5/new cases/year/per million age-related population in children and progresses to need of renal replacement treatment in 5-15% at 10 years and in about 20% at 20 years. The variability of the clinical course anticipates different treatment options. There is an absolute need of validated biomarkers to predict risk of progression and indication for treatment at early stages, when lesions can be reversible. This study aimed to evaluate IgAN progression and its histological and clinical correlates.

Conditions

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Yasar Caliskan, MD · Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-01-31
Completion
2015-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02529722 on ClinicalTrials.gov